Skip to main content
Biosynex logo

Biosynex — Investor Relations & Filings

Ticker · ALBIO ISIN · FR0011005933 LEI · 969500H4BGE1HBLGP566 PA Manufacturing
Open in API
Filings indexed 202 across all filing types
Latest filing 2026-01-22 Regulatory Filings
Country FR France
Listing PA ALBIO

About Biosynex

https://www.biosynex.com/en/

Biosynex is a company that specializes in the design, manufacture, and distribution of medical diagnostic solutions. Its core product line consists of Rapid Diagnostic Tests (RDTs) for both professional use in clinical settings and for self-testing by the general public. The professional portfolio includes point-of-care (POC) instruments, molecular biology diagnostics (such as PCR tests), and a wide array of immunodiagnostic assays. For the consumer market, Biosynex offers various self-tests and a range of prevention and monitoring devices, including thermometers, blood pressure monitors, and pulse oximeters. The company focuses on providing simple, rapid, and effective tools for screening, diagnosis, and prevention.

Recent filings

Filing Released Lang Actions
BIOSYNEX SA: CHEMBIO DIAGNOSTIC SYSTEMS INC., FILIALE DE BIOSYNEX, ANNONCE LE DOUBLE DEPOT A LA FDA DU TEST DPP SYPHILIS TnT SUITE A LA DESIGNATION DE DISPOSITIF INNOVANT (BREAKTHROUGH DEVICE)
Regulatory Filings Classification · 95% confidence The document is a press release issued by BIOSYNEX SA regarding a regulatory submission (FDA) for a medical diagnostic test. It provides details on the product, the clinical context, and the regulatory status. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a simple announcement of a report (RPA). As it is a general corporate regulatory announcement regarding business operations and product development, it falls under the 'Regulatory Filings' (RNS) category.
2026-01-22 French
BIOSYNEX SA: ACTIVITE 2025 - PERSPECTIVES 2026
Earnings Release Classification · 95% confidence The document is a press release from BIOSYNEX dated January 15, 2026, detailing the company's 2025 revenue figures, business performance, and a status update on its ongoing restructuring/safeguard procedure. It provides key financial highlights (revenue, divisional performance) but explicitly states that these figures are non-audited and that the full annual results will be communicated later (April 22, 2026). This fits the definition of an Earnings Release (ER), which is the initial announcement of periodic financial results containing key highlights. FY 2025
2026-01-15 French
BIOSYNEX SA: ACTIVITE 2025 - PERSPECTIVES 2026
Earnings Release Classification · 100% confidence The document is a press release from BIOSYNEX SA titled 'ACTIVITE 2025 – PERSPECTIVES 2026'. It provides preliminary financial highlights (revenue figures) for the fiscal year 2025, business updates, and future outlooks. It explicitly states that the figures are non-audited and mentions that the full annual results will be communicated later (April 2026). According to the filing definitions, an initial announcement of periodic financial results (key highlights only) is classified as an Earnings Release (ER). FY 2025
2026-01-15 French
BIOSYNEX SA: Calendrier financier 2026
Report Publication Announcement Classification · 100% confidence The document is a press release from BIOSYNEX titled 'Calendrier financier 2026' (Financial Calendar 2026). It lists the scheduled dates for the release of annual revenue, annual results, and interim financial reports for the upcoming year. According to the 'Menu vs Meal' rule, this is an announcement regarding the timing of future reports rather than the reports themselves, which fits the definition of a Report Publication Announcement (RPA).
2026-01-06 French
BIOSYNEX SA: Calendrier financier 2026
Report Publication Announcement Classification · 100% confidence The document is a press release from BIOSYNEX SA announcing its 'Calendrier financier 2026' (Financial Calendar 2026). It lists the scheduled dates for the release of annual and quarterly financial results. This type of document is a standard corporate announcement regarding the timing of future report publications, which falls under the 'Report Publication Announcement' (RPA) category according to the provided definitions.
2026-01-06 French
BIOSYNEX SA: DEMISSION DE BRIGITTE GENY DE SON POSTE DADMINISTRATRICE
Board/Management Information Classification · 100% confidence The document is a press release announcing the resignation of a member of the Board of Directors (Brigitte Geny) from BIOSYNEX SA. This falls under the category of board or management changes. While it is a regulatory announcement, the specific content regarding the resignation of an administrator makes 'MANG' the most accurate classification.
2025-12-30 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.